|
|
|
|
LEADER |
00000cam a2200000Mi 4500 |
001 |
EBSCO_on1055262923 |
003 |
OCoLC |
005 |
20231017213018.0 |
006 |
m o d |
007 |
cr |n||||||||| |
008 |
181003s2019 enk o 000 0 eng d |
040 |
|
|
|a YDX
|b eng
|e pn
|c YDX
|d OPELS
|d EBLCP
|d N$T
|d OCLCF
|d OCLCQ
|d MERER
|d D6H
|d OCLCQ
|d AU@
|d LQU
|d UHL
|d OCLCQ
|d OCLCO
|d OCLCA
|d OCLCQ
|d OCLCA
|d OCLCQ
|d S2H
|d OCLCO
|d REDDC
|d VT2
|d OCLCA
|d TEU
|d OCLCQ
|d COM
|d OCLCO
|d OCLCQ
|d SFB
|d OCLCQ
|d OCLCO
|
019 |
|
|
|a 1055043001
|a 1105175151
|a 1105563112
|a 1113291940
|a 1118508330
|a 1124322252
|a 1162061852
|a 1229130895
|a 1235839922
|a 1257368298
|a 1311343720
|a 1311348665
|
020 |
|
|
|a 9780128140024
|q (electronic bk.)
|
020 |
|
|
|a 012814002X
|q (electronic bk.)
|
020 |
|
|
|z 0128140011
|
020 |
|
|
|z 9780128140017
|
029 |
1 |
|
|a AU@
|b 000064199529
|
029 |
1 |
|
|a AU@
|b 000064362748
|
029 |
1 |
|
|a AU@
|b 000068487006
|
029 |
1 |
|
|a AU@
|b 000068464631
|
035 |
|
|
|a (OCoLC)1055262923
|z (OCoLC)1055043001
|z (OCoLC)1105175151
|z (OCoLC)1105563112
|z (OCoLC)1113291940
|z (OCoLC)1118508330
|z (OCoLC)1124322252
|z (OCoLC)1162061852
|z (OCoLC)1229130895
|z (OCoLC)1235839922
|z (OCoLC)1257368298
|z (OCoLC)1311343720
|z (OCoLC)1311348665
|
050 |
|
4 |
|a RS201.N35
|
060 |
|
4 |
|a QV 785
|
072 |
|
7 |
|a MED
|x 071000
|2 bisacsh
|
082 |
0 |
4 |
|a 615.1/9
|2 23
|
049 |
|
|
|a UAMI
|
245 |
0 |
0 |
|a Brain targeted drug delivery systems :
|b a focus on nanotechnology and and nanoparticulates /
|c edited by Huile Gao, Xiaoling Gao.
|
260 |
|
|
|a London :
|b Academic Press,
|c ©2019.
|
300 |
|
|
|a 1 online resource
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
505 |
0 |
|
|a Front Cover; Brain Targeted Drug Delivery Systems: A Focus on Nanotechnology and Nanoparticulates; Copyright; Dedication; Contents; Contributors; Preface; Chapter 1: Introduction and overview; 1. Is it possible to deliver drugs to brain?; 2. What's the major concerns of brain-targeted DDS?; 3. Conclusion; Part I: Physiology and principles for brain targeting drug delivery; Chapter 2: Anatomy and physiology of blood-brain barrier; 1. Introduction; 2. Concept of blood-brain barrier; 3. Neurovascular unit; 3.1. Occludin; 3.2. Claudin; 3.3. Adhesion junctions; 3.4. Junctional adhesion molecules.
|
505 |
8 |
|
|a 3.5. Accessory proteins3.6. Pericytes; 3.7. Neurons; 3.8. Extracellular matrix; 4. Role of astrocytes; 5. Transportation across blood-brain barrier; 6. Types of transport systems at blood-brain barrier; 6.1. Amino acid transport; 6.2. Hexose transport system; 6.3. Monocarboxylate transporter system; 6.4. Organic anion transporter family; 6.5. Organic cation transporter (OCT and OCTN) family; 6.6. Transport of nucleosides; 6.7. Transport of peptides; 6.8. Transport of macromolecules; 6.9. Transport of ions; 6.10. Transcytosis of macromolecules; 7. Conclusions; References.
|
505 |
8 |
|
|a Chapter 3: Recent progress in blood-brain barrier transportation research1. Introduction; 2. Overview of the transport mechanisms at the BBB; 2.1. Carrier-mediated transcytosis; 2.1.1. Glucose transporters; 2.1.2. Large neutral amino acid transporter 1; 2.1.3. Monocarboxylate transporter 1; 2.2. Receptor-mediated transport; 2.2.1. Transferrin receptor; 2.2.2. Insulin receptor; 2.2.3. Low-density lipoprotein receptor-related protein; 2.3. Adsorptive-mediated transcytosis; 3. Strategies for improving CNS delivery of therapeutics; 3.1. Enhanced paracellular transport.
|
505 |
8 |
|
|a 3.2. Improving physicochemical properties of CNS-active drugs3.3. Drug modification with targeting moieties; 3.4. Nanocarrier-based drug delivery; 3.5. Cell-based drug delivery; 4. Future perspectives; References; Chapter 4: In vitro and in vivo models of BBB to evaluate brain targeting drug delivery; 1. Introduction; 2. The neurovascular unit; 2.1. Endothelial cells; 2.2. Pericytes; 2.3. Astrocytes; 2.4. Molecular structure of the junction; 2.4.1. Tight junctions; 2.4.2. Adherens junction; 3. Movement through the blood-brain barrier; 3.1. Passive diffusion; 3.2. Carrier-mediated transport.
|
505 |
8 |
|
|a 3.3. Active efflux pumps3.4. Transcytosis; 3.5. Cell-mediated transport; 4. In vitro models of BBB for assessing drug delivery; 4.1. Methods for measuring permeability; 4.1.1. TEER (trans-endothelial electric resistance) measurement; 4.1.2. FITC-dextran and sodium fluorescein; 4.1.3. Lucifer yellow; 4.1.4. Evans blue dye; 4.1.5. Horseradish peroxidase (HRP); 4.1.6. Mannitol/sucrose/inulin (radiolabeled); 4.2. In vitro models; 4.2.1. Noncell-based (synthetic) in vitro models; 4.2.1.1. Immobilized artificial membrane (IAM) chromatography; 4.2.1.2. Parallel artificial membrane permeability assay.
|
504 |
|
|
|a Includes bibliographical references and index.
|
520 |
|
|
|a Brain Targeted Drug Delivery Systems: A Focus on Nanotechnology and Nanoparticulates provides a guide on nanoparticulates to both academic and industry researchers. The book discusses key points in the development of brain targeted drug delivery, summarizes available strategies, and considers the main problems and pitfalls evidenced in current studies on brain targeted drug delivery systems. As the brain is the most important organ in the human body, and disorders of the central nervous system (CNS) are the most serious threat to human life, this book highlights advances and new research in drug delivery methods to the brain. Provides an overview of brain targeting drug delivery that is useful to both academic and industry-based researchers; Discusses key points in developing brain targeting drug delivery systems; Summarizes and presents currently available strategies for brain targeting drug delivery; Covers not only current studies and their strengths, but also gives insight into the pitfalls of current research.
|
590 |
|
|
|a eBooks on EBSCOhost
|b EBSCO eBook Subscription Academic Collection - Worldwide
|
650 |
|
0 |
|a Nanoparticles.
|
650 |
|
0 |
|a Drug delivery systems.
|
650 |
|
0 |
|a Blood-brain barrier.
|
650 |
|
2 |
|a Nanoparticles
|x therapeutic use
|
650 |
|
2 |
|a Drug Delivery Systems
|
650 |
|
2 |
|a Blood-Brain Barrier
|
650 |
|
2 |
|a Nanoparticles
|
650 |
|
6 |
|a Nanoparticules.
|
650 |
|
6 |
|a Systèmes d'administration de médicaments.
|
650 |
|
6 |
|a Barrière hémato-encéphalique.
|
650 |
|
7 |
|a MEDICAL
|x Pharmacology.
|2 bisacsh
|
650 |
|
7 |
|a Drug delivery systems
|2 fast
|
650 |
|
7 |
|a Nanomedicine
|2 fast
|
700 |
1 |
|
|a Gao, Huile.
|
700 |
1 |
|
|a Gao, Xiaoling.
|
776 |
0 |
8 |
|i Print version:
|t Brain targeted drug delivery systems.
|d London : Academic Press, ©2019
|z 0128140011
|z 9780128140017
|w (OCoLC)1028228863
|
856 |
4 |
0 |
|u https://ebsco.uam.elogim.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1789754
|z Texto completo
|
938 |
|
|
|a ProQuest Ebook Central
|b EBLB
|n EBL5522117
|
938 |
|
|
|a EBSCOhost
|b EBSC
|n 1789754
|
938 |
|
|
|a YBP Library Services
|b YANK
|n 15733198
|
994 |
|
|
|a 92
|b IZTAP
|